Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2025-04-28 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2024 Annual General Meeting (AGM) of Shenzhen Haiwang Bioengineering Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, and instructions for shareholders to participate either in person or via online voting. The document does not contain financial statements or detailed financial performance data but rather logistical and procedural information related to the AGM. The document length is 4374 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself.
2025-04-28 Chinese
深圳市海王生物工程股份有限公司营业收入扣除情况表专项核查报告
Regulatory Filings
2025-04-28 Chinese
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special opinion on the independence of the company's independent directors, referencing regulatory guidelines and internal company rules. It assesses the independence of specific directors for the year 2024, confirming compliance with relevant independence requirements. There is no financial data, no report publication, no voting results, no management changes, and no other report types indicated. This is a governance-related document focused on board independence and compliance with governance rules. Therefore, it fits best under Governance Information (CGR). The document length is short but contains substantive content about governance, not just an announcement or certification.
2025-04-28 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including revenue, net profit, assets, and quarterly breakdowns. It also discusses company business segments, patents, shareholder information, and significant corporate events during the year. The length is over 9,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with an official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-28 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2025-04-28 Chinese
2024年度独立董事述职报告（张华）
Board/Management Information Classification · 95% confidence The document is titled '2024 年度独立董事述职报告（张华）' which translates to '2024 Annual Independent Director's Work Report (Zhang Hua)'. It is a detailed report by an independent director about his duties, attendance at board meetings, committee work, communication with auditors, and overall evaluation of the company's governance and operations during the 2024 fiscal year. The content focuses on the independent director's responsibilities, oversight, and governance activities rather than financial results or audit opinions alone. It is not an announcement or a brief summary but a substantive report on management and board activities. This fits best under the category of Board/Management Information (MANG), which covers announcements related to changes or reports from the company's board or senior management. The document is not a full annual report (10-K), audit report (AR), or regulatory filing (RNS), nor is it a proxy statement or remuneration report. Therefore, the classification is MANG with high confidence.
2025-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.